Al Altomari, Chairman and CEO
Agile Therapeutics
Charlene Banard, Global Head of Technical Operations Cell & Gene Therapy Strategy, Innovation Pipeline and PMO
Novartis
Jeffrey Berkowitz, Board Member
H. Lundbeck A/S
Liz Bywater, Ph.D., President
Bywater Consulting Group
Ron Cohen, M.D., President & CEO
Acorda Therapeutics
Laurie Cooke, CEO
Healthcare Businesswomen's Association (HBA)
John Crowley, Chairman and CEO
Amicus Therapeutics
Rich Daly, Chief Operating Officer
Beyond Spring
Raúl Díaz, Animal Health Large Molecules Biopharm. Operations
MSD, Montes Claros, MG, Brazil
Tom Dilenge, President, Advocacy, Law & Public Policy Division
Biotechnology Innovation Organization
Joseph Ferra, CFO
Syros Pharmaceuticals
Anu Hans, VP, Strategic Initiatives
Janssen Supply Chain
Fred Hassan, Managing Director
Warburg Pincus
Paul Hastings, President and CEO
Nkarta Therapeutics
Axel Hoos, M.D., Ph.D., SVP Oncology R&D
GSK
John Hubbard, Ph.D., Emeritus Editorial Advisory Board Member
Life Science Leader
Mitchell Katz, Ph.D., Vice President, Development Operations
Ferring Pharmaceutical, Inc.
Mary Rose Keller, VP, Clinical Operations
Heron Therapeutics
Rachel King, CEO
GlycoMimetics
Suresh Kumar, Former EVP External Affairs
Sanofi
John LaMattina, Ph.D., Sr. Partner
PureTech Health
Jacks Lee, SVP global manufacturing and supply
Merck
Martin Lehr, CEO
Context Therapeutics
Sandy Macrae, Ph.D., President & CEO
Sangamo Therapeutics
Ken Moch, Former President & CEO
Cognition Therapeutics
Carol Nacy, Ph.D., CEO
Sequella
Francois Nader, M.D., Chairman of the Board
Acceleron Pharma
Sandra Poole, COO
Candel Therapeutics
Dennis Purcell, Founder & Sr. Advisor
Aisling Capital
David Pyott, Chairman of the Board
Bioniz Therapeutics
Chandra Ramanathan, Ph.D., MBA, VP & Head, East Coast Innovation Center
Bayer
Stephen Rapundalo, Ph.D., President & CEO
MichBio
Pamela Reilly Contag, Ph.D., Cofounder and CEO
BioEclipse Therapeutics
John Reynders, Ph.D., VP, R&D strategy, program management, and data sciences
Alexion
James Robinson, Emeritus Editorial Advisory Board Member
Life Science Leader
Tomasz Sablinski, M.D., Ph.D., co-founder and board member
Transparency Life Sciences
Jim Scibetta, CEO
Maverick Therapeutics
Chhaya Shah, SVP Technical Operations
Radius Health
Allan Shaw, Independent Consultant
Brandi Simpson, VP Business and Corporate Development
Voyager Therapeutics
Andrew Skibo, Emeritus Editorial Advisory Board Member, Life Science Leader
MedImmune / AstraZeneca
Jason Urban, Ph.D., Sr. Dir. Quality Risk Management
Alexion
Thomas Wiggans, Founder, CEO, Chairman
Dermira
Leslie Williams, Entrepreneur, Executive, Board Member, Mentor
ImmusanT
Tim Wright, CEO
MiMedx

IN THIS MONTH'S ISSUE

  • Most Favored Nation Pricing Temporarily Halted By Courts

    In late December, the courts halted President Trump’s international reference-pricing scheme, the Most Favored Nation model, saying the administration had improperly attempted to implement a radical change in Medicare reimbursement policy.

  • Going Public In Mid-Pandemic

    Just as the COVID pandemic hit, Timber Pharma was planning on going public. But that wasn’t the only challenge the company faced in the months ahead.

  • 5 Elements Of A Long-Term Partnership Strategy

    Throughout my career, I have seen partnerships that succeed and those that fail. Through this experience, I have been able to identify what it takes to build and maintain partnerships that stand the test of time.

  • Benefits Of Beantown Biotech And Lessons For Life Science Leaders

    I have had the opportunity to experience and contribute to the thriving life sciences industry in Massachusetts, and I can say that it has all of the components needed to ultimately bring new treatments forward for patients.

  • Increasing Patient Diversity In Clinical Trials

    The COVID-19 pandemic has spotlighted healthcare’s biggest shortfalls. One of the most glaring problems sounds like it should be simple to resolve, but it has actually been challenging to implement — diversity in clinical trials.

@LIFESCILEADER1